Shopping Cart 0
Cart Subtotal
AED 0

Vertex Pharmaceuticals Inc (VRTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Vertex Pharmaceuticals Inc (Vertex) is a biotechnology company that carries out the discovery, development and commercialization of transformative drugs for the treatment of serious and life-threatening diseases. The company product portfolio includes Orkambi (ivacaftor/lumacaftor) and Kalydeco (ivacaftor) for the treatment of cystic fibrosis (CF). Through its research and development (R&D) efforts, the company focuses on influenza, cancer, neurological diseases and disorders including pain and cystic fibrosis. Vertex has R&D centers and commercial offices in North America, South America, Europe and Australia. The company offers its products in the US, Europe, Australia and Canada. Vertex is headquartered in Boston, Massachusetts, the US.

Vertex Pharmaceuticals Inc (VRTX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Vertex Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Vertex Pharma Acquires CTP-656 from Concert Pharma 13

Vertex Pharma Acquires Cystic Fibrosis Assets from AmorChem 15

Partnerships 16

Vertex Pharma Enters into Partnership Agreement with Genomics 16

Q-State Biosciences Enters into Agreement with Vertex Pharmaceuticals 17

X-Chem Enters into Agreement with Vertex Pharma 18

Vertex Pharma Enters into Research Collaboration with CRISPR Therapeutics 19

Vertex Pharma Enters into Co-Development Agreement with Parion Sciences 20

Licensing Agreements 21

Vertex Pharma Enters into Licensing Agreement with CRISPR Therapeutics 21

Merck Enters into Licensing Agreement with Vertex Pharma 22

Vertex Pharma Enters into Licensing Agreement with Moderna Therapeutics 23

Enterome Bioscience Enters into Licensing Agreement with Vertex Pharma 24

EIP Pharma Enters into Licensing Agreement with Vertex Pharma 25

Vertex Pharma Enters into Licensing Agreement with BioAxone Biosciences for VX-210 26

Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 27

Asset Transactions 28

Trek Therapeutics Acquires Rights to Two Antiviral Inhibitors from Vertex Pharma 28

Spero Therapeutics Acquires Rights to Novel Gyrase Inhibitors from Vertex Pharma 29

Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For USD 152 Million 30

Vertex Pharmaceuticals Inc-Key Competitors 31

Vertex Pharmaceuticals Inc-Key Employees 32

Vertex Pharmaceuticals Inc-Locations And Subsidiaries 34

Head Office 34

Other Locations & Subsidiaries 34

Recent Developments 36

Financial Announcements 36

Oct 24, 2018: Vertex reports third-quarter 2018 financial results 36

Jul 25, 2018: Vertex reports second-quarter 2018 financial results 37

Apr 26, 2018: Vertex Reports First-Quarter 2018 Financial Results 39

Jan 31, 2018: Vertex Reports Full-Year and Fourth-Quarter 2017 Financial Results 41

Oct 25, 2017: Vertex Reports Third-Quarter 2017 Financial Results 44

Jul 26, 2017: Vertex Reports Second-Quarter 2017 Financial Results 47

Apr 27, 2017: Vertex Reports First-Quarter 2017 Financial Results 50

Jan 25, 2017: Vertex Reports Full-Year and Fourth-Quarter 2016 Financial Results 53

Corporate Communications 55

Aug 23, 2018: Vertex names Ludovic Fenaux as senior vice president, international commercial operations 55

Jun 14, 2018: The Vertex Foundation and Employees Donate USD 1 Million Through Matching Gift Program 56

Mar 29, 2018: Vertex Pharmaceuticals Names Kimberly A. White As Senior Vice President And Chief Communications Officer 57

Feb 26, 2018: Vertex Names Reshma Kewalramani As Chief Medical Officer 58

Oct 17, 2017: Vertex Announces 10-Year, USD 500 Million Corporate Giving Commitment 59

Sep 06, 2017: Vertex Appoints Tom Graney as Senior Vice President and Chief Financial Officer 60

Jun 08, 2017: Vertex Names Dr. Alan Garber, Provost of Harvard University, to its Board of Directors 61

Government and Public Interest 62

Oct 04, 2018: Vertex's cystic fibrosis drugs become publicly available in Denmark 62

Nov 01, 2017: Vertex Announces New USD 750,000 Program to Support the Work of the Next Generation of Cystic Fibrosis Researchers 63

May 04, 2017: Vertex Grants USD 1 Million to 15 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis 64

Product News 65

07/18/2017: Vertex Provides Update on VX-445 development program 65

05/08/2018: Evaluating the Impact of Precision Medicine: How Ivacaftor Reduces Hospitalizations of Patients with Cystic Fibrosis 66

Product Approvals 67

Jan 20, 2017: Concert Pharmaceuticals Receives FDA Orphan Drug Designation for CTP-656 for the Treatment of Cystic Fibrosis 67

Clinical Trials 68

Apr 26, 2018: Vertex Initiates Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis 68

Feb 21, 2018: Vertex Initiates First Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis 70

Feb 01, 2018: Vertex Selects Next-Generation Corrector, VX-445, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis 71

Feb 01, 2018: Vertex Selects Next-Generation Corrector, VX-659, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis 73

Jul 18, 2017: Vertex Announces Positive Phase 2 Data from Triple Combination Regimen with VX-440 75

Jul 18, 2017: Vertex Announces Positive Phase I Data from Triple Combination Regimen with VX-659 77

Jan 17, 2017: Concert Pharmaceuticals Provides Further Details on CTP-656 Development in U.S. and Europe 79

Other Significant Developments 80

Jan 08, 2017: Vertex Provides Update on Business and Financial Performance and Research and Development Programs 80

Appendix 83

Methodology 83

About GlobalData 83

Contact Us 83

Disclaimer 83


List Of Figure

List of Figures

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Vertex Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Vertex Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Vertex Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Vertex Pharma Acquires CTP-656 from Concert Pharma 13

Vertex Pharma Acquires Cystic Fibrosis Assets from AmorChem 15

Vertex Pharma Enters into Partnership Agreement with Genomics 16

Q-State Biosciences Enters into Agreement with Vertex Pharmaceuticals 17

X-Chem Enters into Agreement with Vertex Pharma 18

Vertex Pharma Enters into Research Collaboration with CRISPR Therapeutics 19

Vertex Pharma Enters into Co-Development Agreement with Parion Sciences 20

Vertex Pharma Enters into Licensing Agreement with CRISPR Therapeutics 21

Merck Enters into Licensing Agreement with Vertex Pharma 22

Vertex Pharma Enters into Licensing Agreement with Moderna Therapeutics 23

Enterome Bioscience Enters into Licensing Agreement with Vertex Pharma 24

EIP Pharma Enters into Licensing Agreement with Vertex Pharma 25

Vertex Pharma Enters into Licensing Agreement with BioAxone Biosciences for VX-210 26

Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 27

Trek Therapeutics Acquires Rights to Two Antiviral Inhibitors from Vertex Pharma 28

Spero Therapeutics Acquires Rights to Novel Gyrase Inhibitors from Vertex Pharma 29

Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For USD 152 Million 30

Vertex Pharmaceuticals Inc, Key Competitors 31

Vertex Pharmaceuticals Inc, Key Employees 32

Vertex Pharmaceuticals Inc, Subsidiaries 34

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Vertex Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Vertex Pharmaceuticals Inc (Vertex) is a biotechnology company that carries out the discovery, development and commercialization of transformative drugs for the treatment of serious and life-threatening diseases. The company product portfolio includes Orkambi (ivacaftor/lumacaftor) and Kalydeco (ivacaftor) for the treatment of cystic fibrosis (CF). Through its research and development (R&D) efforts, the company focuses on influenza, cancer, neurological diseases and disorders including pain and cystic fibrosis. Vertex has R&D centers and commercial offices in North America, South America, Europe and Australia. The company offers its products in the US, Europe, Australia and Canada. Vertex is headquartered in Boston, Massachusetts, the US.

Vertex Pharmaceuticals Inc (VRTX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Vertex Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Vertex Pharma Acquires CTP-656 from Concert Pharma 13

Vertex Pharma Acquires Cystic Fibrosis Assets from AmorChem 15

Partnerships 16

Vertex Pharma Enters into Partnership Agreement with Genomics 16

Q-State Biosciences Enters into Agreement with Vertex Pharmaceuticals 17

X-Chem Enters into Agreement with Vertex Pharma 18

Vertex Pharma Enters into Research Collaboration with CRISPR Therapeutics 19

Vertex Pharma Enters into Co-Development Agreement with Parion Sciences 20

Licensing Agreements 21

Vertex Pharma Enters into Licensing Agreement with CRISPR Therapeutics 21

Merck Enters into Licensing Agreement with Vertex Pharma 22

Vertex Pharma Enters into Licensing Agreement with Moderna Therapeutics 23

Enterome Bioscience Enters into Licensing Agreement with Vertex Pharma 24

EIP Pharma Enters into Licensing Agreement with Vertex Pharma 25

Vertex Pharma Enters into Licensing Agreement with BioAxone Biosciences for VX-210 26

Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 27

Asset Transactions 28

Trek Therapeutics Acquires Rights to Two Antiviral Inhibitors from Vertex Pharma 28

Spero Therapeutics Acquires Rights to Novel Gyrase Inhibitors from Vertex Pharma 29

Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For USD 152 Million 30

Vertex Pharmaceuticals Inc-Key Competitors 31

Vertex Pharmaceuticals Inc-Key Employees 32

Vertex Pharmaceuticals Inc-Locations And Subsidiaries 34

Head Office 34

Other Locations & Subsidiaries 34

Recent Developments 36

Financial Announcements 36

Oct 24, 2018: Vertex reports third-quarter 2018 financial results 36

Jul 25, 2018: Vertex reports second-quarter 2018 financial results 37

Apr 26, 2018: Vertex Reports First-Quarter 2018 Financial Results 39

Jan 31, 2018: Vertex Reports Full-Year and Fourth-Quarter 2017 Financial Results 41

Oct 25, 2017: Vertex Reports Third-Quarter 2017 Financial Results 44

Jul 26, 2017: Vertex Reports Second-Quarter 2017 Financial Results 47

Apr 27, 2017: Vertex Reports First-Quarter 2017 Financial Results 50

Jan 25, 2017: Vertex Reports Full-Year and Fourth-Quarter 2016 Financial Results 53

Corporate Communications 55

Aug 23, 2018: Vertex names Ludovic Fenaux as senior vice president, international commercial operations 55

Jun 14, 2018: The Vertex Foundation and Employees Donate USD 1 Million Through Matching Gift Program 56

Mar 29, 2018: Vertex Pharmaceuticals Names Kimberly A. White As Senior Vice President And Chief Communications Officer 57

Feb 26, 2018: Vertex Names Reshma Kewalramani As Chief Medical Officer 58

Oct 17, 2017: Vertex Announces 10-Year, USD 500 Million Corporate Giving Commitment 59

Sep 06, 2017: Vertex Appoints Tom Graney as Senior Vice President and Chief Financial Officer 60

Jun 08, 2017: Vertex Names Dr. Alan Garber, Provost of Harvard University, to its Board of Directors 61

Government and Public Interest 62

Oct 04, 2018: Vertex's cystic fibrosis drugs become publicly available in Denmark 62

Nov 01, 2017: Vertex Announces New USD 750,000 Program to Support the Work of the Next Generation of Cystic Fibrosis Researchers 63

May 04, 2017: Vertex Grants USD 1 Million to 15 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis 64

Product News 65

07/18/2017: Vertex Provides Update on VX-445 development program 65

05/08/2018: Evaluating the Impact of Precision Medicine: How Ivacaftor Reduces Hospitalizations of Patients with Cystic Fibrosis 66

Product Approvals 67

Jan 20, 2017: Concert Pharmaceuticals Receives FDA Orphan Drug Designation for CTP-656 for the Treatment of Cystic Fibrosis 67

Clinical Trials 68

Apr 26, 2018: Vertex Initiates Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis 68

Feb 21, 2018: Vertex Initiates First Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis 70

Feb 01, 2018: Vertex Selects Next-Generation Corrector, VX-445, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis 71

Feb 01, 2018: Vertex Selects Next-Generation Corrector, VX-659, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis 73

Jul 18, 2017: Vertex Announces Positive Phase 2 Data from Triple Combination Regimen with VX-440 75

Jul 18, 2017: Vertex Announces Positive Phase I Data from Triple Combination Regimen with VX-659 77

Jan 17, 2017: Concert Pharmaceuticals Provides Further Details on CTP-656 Development in U.S. and Europe 79

Other Significant Developments 80

Jan 08, 2017: Vertex Provides Update on Business and Financial Performance and Research and Development Programs 80

Appendix 83

Methodology 83

About GlobalData 83

Contact Us 83

Disclaimer 83


List Of Figure

List of Figures

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Vertex Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Vertex Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Vertex Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Vertex Pharma Acquires CTP-656 from Concert Pharma 13

Vertex Pharma Acquires Cystic Fibrosis Assets from AmorChem 15

Vertex Pharma Enters into Partnership Agreement with Genomics 16

Q-State Biosciences Enters into Agreement with Vertex Pharmaceuticals 17

X-Chem Enters into Agreement with Vertex Pharma 18

Vertex Pharma Enters into Research Collaboration with CRISPR Therapeutics 19

Vertex Pharma Enters into Co-Development Agreement with Parion Sciences 20

Vertex Pharma Enters into Licensing Agreement with CRISPR Therapeutics 21

Merck Enters into Licensing Agreement with Vertex Pharma 22

Vertex Pharma Enters into Licensing Agreement with Moderna Therapeutics 23

Enterome Bioscience Enters into Licensing Agreement with Vertex Pharma 24

EIP Pharma Enters into Licensing Agreement with Vertex Pharma 25

Vertex Pharma Enters into Licensing Agreement with BioAxone Biosciences for VX-210 26

Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 27

Trek Therapeutics Acquires Rights to Two Antiviral Inhibitors from Vertex Pharma 28

Spero Therapeutics Acquires Rights to Novel Gyrase Inhibitors from Vertex Pharma 29

Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For USD 152 Million 30

Vertex Pharmaceuticals Inc, Key Competitors 31

Vertex Pharmaceuticals Inc, Key Employees 32

Vertex Pharmaceuticals Inc, Subsidiaries 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Vertex Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.